Search
Mesterolone
go.drugbank.com/drugs/DB13587InvestigationalIt is inactivated by 3α-hydroxysteroid dehydrogenase in skeleta muscules so it is considered a weak androgen. It is not a substrate for aromatase so it is not converted into estrogen.
Lormetazepam
go.drugbank.com/drugs/DB13872ApprovedIt is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.
Synonyms: N-MethyllorazepamPhosphoaminophosphonic acid guanylate ester
go.drugbank.com/drugs/DB02082ExperimentalA non-hydrolyzable analog of GTP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It binds tightly to G-protein in the presence of Mg2+.
Synonyms: Gpp(NH)pGlycoPEG-GCSF
go.drugbank.com/drugs/DB06022ExperimentalGlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.
Gabapentin enacarbil
go.drugbank.com/drugs/DB08872ApprovedGabapentin enacarbil is marketed under the name Horizant. It is a prodrug of gabapentin, and indicated in adults for the treatment of Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN).
Lomefloxacin
go.drugbank.com/drugs/DB00978ApprovedLomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.
Benidipine
go.drugbank.com/drugs/DB09231Investigational[A31948] It was originated in Japan by Kyowa Hakko, it is submitted for FDA approval and it is currently available in some Asian countries like India and Japan.[L1385, L1386]
Hu-rhEGF-rP64k/Mont
go.drugbank.com/drugs/DB15781Investigationalfor the treatment of advanced non-small cell lung cancer (NSCLC). … Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated
SIG-007
go.drugbank.com/drugs/DB17710ExperimentalDeveloped by Sigilon Therapeutics, t is being investigated for the treatment of Fabry Disease.[L46153] … SIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A.